Cystic Fibrosis-Related Diabetes Research Program Research Studies

The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%)

The Children’s Hospital of Philadelphia is seeking healthy adolescents and young adults ages 16-22 years old, to participate in the Muscle Accrual in Cystic Fibrosis Research Study.

Insulin therapy, commonly given as multiple daily injection therapy, is the only recommended treatment for Cystic Fibrosis Related Diabetes (CFRD).